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Abstract
Background: ARHI is a Ras-related imprinted gene that inhibits cancer cell growth and motility. ARHI is
downregulated in the majority of breast cancers, and loss of its expression is associated with its progression from
ductal carcinoma in situ (DCIS) to invasive disease. In ovarian cancer, re-expression of ARHI induces autophagy and
leads to autophagic death in cell culture; however, ARHI re-expression enables ovarian cancer cells to remain
dormant when they are grown in mice as xenografts. The purpose of this study is to examine whether ARHI
induces autophagy in breast cancer cells and to evaluate the effects of ARHI gene re-expression in combination
with paclitaxel.
Methods: Re-expression of ARHI was achieved by transfection, by treatment with trichostatin A (TSA) or by a
combination of TSA and 5-aza-2’-deoxycytidine (DAC) in breast cancer cell cultures and by liposomal delivery of
ARHI in breast tumor xenografts.
Results: ARHI re-expression induces autophagy in breast cancer cells, and ARHI is essential for the induction of
autophagy. When ARHI was re-expressed in breast cancer cells treated with paclitaxel, the growth inhibitory effect
of paclitaxel was enhanced in both the cell culture and the xenografts. Although paclitaxel alone did not induce
autophagy in breast cancer cells, it enhanced ARHI-induced autophagy. Conversely, ARHI re-expression promoted
paclitaxel-induced apoptosis and G2/M cell cycle arrest.
Conclusions: ARHI re-expression induces autophagic cell death in breast cancer cells and enhances the inhibitory
effects of paclitaxel by promoting autophagy, apoptosis, and G2/M cell cycle arrest.
Background
Breast cancer remains a leading cause of morbidity and
mortality in women [1]. Decreasing the recurrence and
progression of breast cancer remains a challenge world-
wide. Paclitaxel, a naturally occurring anti-microtubule
agent that causes mitotic arrest, induces apoptosis in a
variety of tumor types [2]. In multiple clinical trials,
paclitaxel significantly improved the rates of those who
became disease-free and the overall survival rate in
breast cancer patients [3-6]. It has become an integral
component of first-line adjuvant chemotherapy [7].
Despite the improved efficacy of adjuvant regimens, the
recurrence of metastatic disease still contributes to the
deaths of hundreds of thousands of women worldwide
annually. New approaches are needed to improve the
efficacy of paclitaxel.
ARHI encodes a small GTP-binding protein belonging
to the Ras/Rap superfamily, which has the characteris-
tics of a tumor suppressor gene in ovarian and breast
cancers, despite sharing 54-59% homology with Ras
proto-oncogenes [8]. ARHI is expressed in normal
breast epithelial cells, but it is dramatically downregu-
lated in more than 70% of breast cancers. Loss of ARHI
expression has been linked to tumor progression from
in situ to invasive cancer [9].
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ARHI is one of ~70 human genes known to be
imprinted. The maternal copy is silenced early in
embryonic development, and ARHI is expressed only
from the paternal allele in all normal cells. As an
imprinted gene, loss of ARHI function can be achieved
with a “single hit” during carcinogenesis. In cancers
tested to date, no mutations of ARHI have been found
in the coding and promoter regions, but loss of ARHI
expression can occur through the loss of heterozygosity,
which is observed in 40% of breast cancers [10]. Epige-
netic regulation also occurs through downregulation of
the paternal allele by DNA hypermethylation, histone
deacetylation, and transcriptional regulation. Our pre-
vious work has demonstrated that transcriptional repres-
sor complexes, including DNA methyltransferase,
histone deacetylase (HDAC) and other repressors, inac-
tivate the ARHI gene, and ARHI expression is restored
by treatment with the demethylating agent 5-aza-2’-
deoxycytidine (DAC) and the HDAC inhibitor trichosta-
tin A (TSA) [11,12].
Our recent findings have shown that re-expression of
ARHI in ovarian cancer cell lines induces autophagy
and leads to autophagic death in cell culture. When
ARHI is upregulated in human xenografts, autophagy is
induced. However, cancer cells do not die; they remain
dormant and grow promptly when ARHI levels are
reduced. Inhibition of autophagy with chloroquine inhi-
bits the outgrowth of dormant cells, which is consistent
with the possibility that ARHI-induced autophagy facili-
tates the survival of dormant cancer cells [13]. Whether
re-expression of ARHI can induce autophagy in breast
cancer cells has not been previously studied. Similarly,
little is known regarding the role of autophagy in the
response to cytotoxic chemotherapy. Our present study
examines whether ARHI can induce autophagy in breast
cancer cells and evaluates the effect of ARHI re-expres-
sion on the sensitivity of breast cancer cells to paclitaxel.
Methods
Cell culture and reagents
The human breast cancer cell lines SKBr3 and MDA-
MB-231 were maintained as described previously [12].
TSA, DAC, rapamycin and paclitaxel were purchased
from Sigma (St. Louis, MO). In cell culture, paclitaxel
was used at concentrations of 2 nM-4 nM, DAC was
used at a concentration of 800 nM, and TSA was used
at concentrations of 40 nM-200 nM, depending on the
particular cell lines and experiments. The antibodies
against ARHI were generated in our laboratory [14].
The antibodies against myosin-associated protein light
chain 3 (MAP-LC3), pAKT, AKT, pmTOR, and mTOR
were purchased from Cell Signaling Technology
(Danvers, MA), the anti-GAPDH antibody was pur-
chased from Jingmei Bio Co. (Shanghai, China), and the
anti-b-actin antibody was purchased from Sigma. The
siRNAs were purchased from Dharmacon Research
(Lafayette, CO).
Cell proliferation assay
Sulforhodamine B (SRB) was used to detect the effect of
drugs on the proliferation of breast cancer cells. The
cells were seeded in 96-well plates and incubated with
paclitaxel, TSA, or a combination of paclitaxel and TSA
for three days. The culture medium was changed daily
to maintain the desired concentration of drugs. After
72 hours, 50 μl of 30% trichloroacetic acid was added
for 60 min at 4°C. After washing and drying the plate,
100 μl of 0.4% SRB was added for 30 min. Next, the
plate was rinsed with 0.1% acetic acid and air dried, and
100 μl of Tris base (10 mmol/L) was added before shak-
ing the plate for 5 min. The SRB value was measured at
a wavelength of 570 nm. The experiment was performed
in sextuplicate and repeated three times.
Real-time RT-PCR
The total cellular RNA was extracted using Trizol (Invi-
trogen, Carlsbad, CA). The first strand cDNA synthesis
was carried out with a RevertAid™ first strand cDNA
synthesis kit (MBI Fermentas Co., Lithuania) using 2 μg
of total RNA and oligo(dT)12-18 primers. The quantitative
PCR reactions included 2 μl of cDNA and 10 μl of SYBR
Green Master Mix (TaKaRa Bio Inc., Dalian, China) with
a pair of primers. The reactions were monitored on the
ABI PRISM 7000 sequence system (Applied Biosystems
Co., Foster City, CA) as described in the manufacturer’s
protocol. The levels of ARHI mRNA were calculated
using the equation 2-ΔΔCT and normalized to human
GAPDH mRNA levels. The primer sequences for real-
time quantitative PCR of ARHI and GAPDH were
designed by Sengon Bio Co. (Shanghai, China). The spe-
cific primer sequences for ARHI were as follows: forward,
5’-TCCGAGCAGCGCATTTGT-3’ and reverse, 5’-
GGAGCCAAAGCTGGCGTTAC-3’. Primer sequences
for GAPDH were as follows: forward, 5’-GCACCGT-
CAAGGCTGAGAAC-3’ and reverse, 5’-TGGTGAA-
GACGCCAGTGGA-3’.
Flow cytometry analysis of acidic vesicular organelles
(AVO)
The cells (1-5 × 105/well) were seeded in six-well plates
and incubated overnight. The control and treated cells
were stained with acridine orange (Sigma) at a final con-
centration of 1 μg/ml for a period of 15 min at 37°C
while avoiding light. After washing twice with PBS, the
cells were trypsinized, suspended in PBS containing 1%
FBS and analyzed immediately. The fluorescence emis-
sion was measured by flow cytometry (FACS Calibur)
(BD, Franklin Lakes, NJ) through the FL1/FL3 channels
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using CellQuest 7.0 software (Beckman Coulter Co.,
CA).
Detection of autophagy with LC3 localization
The SKBr3 cells were co-transfected with pcDNA3-ARHI
and GFP-LC3 (provided by N. Mizushima and T. Yoshi-
mori, National Institute for Basic Biology, Okazaki, Japan)
using Lipofectamine™ 2000 (Invitrogen); a pcDNA3 vec-
tor was used as a control. pcDNA3-ARHI was con-
structed by inserting ARHI cDNA into a pcDNAS3
vector as previous reported [8]. The cells transfected with
GFP-LC3 were also treated with rapamycin (50 nM) as a
positive control to induce autophagy. Forty-eight hours
after transfection, the cells were fixed with 4% parafor-
maldehyde for 15 min in the dark, then washed and
examined under fluorescence microscopy.
siRNA transfection
The ARHI siRNAs were a mixture of four designed siR-
NAs; the efficiency of the knock-down was confirmed by
the manufacturer (Dharmacon Research, Lafayette, CO).
SKBr3 cells were transfected with the control or the ARHI
siRNAs, using the Transfectin #4 reagent (Dharmacon
Research), as previously reported [13]. Briefly, a mixture of
siRNAs (100 nM final concentration) and transfection
reagents were incubated for 20 min at room temperature.
This mixture was then added to the cells. After 48 hrs of
incubation with the siRNAs and the transfection reagents,
the cells were harvested for the measurement of protein
and mRNA expression. The drugs were added 24 hrs
before harvesting. For experiments with serial transfec-
tions, cells were transfected with the siRNAs, using the
Transfectin #4 reagent on day one and with additional
GFP-LC3 plasmid using Lipofectamine 2000 on day two.
The cells were harvested for the measurement of protein
expression or fixed for fluorescence microscopy analysis
24 hrs after the final transfection.
Cell cycle and apoptosis analysis
The breast cancer cells (1-5 × 105/well) were plated and
incubated overnight. The control and treated cells were
trypsinized, collected in PBS and fixed on ice with 1%
paraformaldehyde, followed by 70% cold ethanol. After
treatment with 10 μg/ml RNase, the cells were stained
with 50 μg/ml propidium iodide (PI, Sigma) for 15 min
at room temperature for cell cycle analysis. The apopto-
tic cells were detected with Annexin V/PI double stain-
ing. The cells were trypsinized and stained with
Annexin V and PI following the manufacturer’s instruc-
tions for the Vybrant ® Apoptosis Assay Kit (Invitro-
gen). The stained cells were analyzed by flow cytometry.
Cell cycle information was acquired with CellQuest 7.0
software, and the results were analyzed further using
ModFit3.0 software.
Western blot analysis
The western blot analysis was performed as previously
described [14]. Briefly, proteins from total cell lysates
were separated using 10-15% SDS-PAGE and then
transferred to PVDF membranes (Millipore, Billerica,
MA). The membranes were blocked, washed, and incu-
bated with specific primary antibodies. The primary
antibody incubation was followed by incubation with
HRP-conjugated secondary antibodies (Jingmei Bio Co.
Shanghai, China). The bands were detected with an
enhanced chemiluminescence assay (Pierce Biotechnol-
ogy, South Haven, MI).
Transmission Electron Microscopy (TEM)
The tumor specimens were prepared and processed for
electron microscopy. Thin sections were observed with
a Philips CM120 transmission electron microscope
(Philips, Netherlands). The digital images of the micro-
graphs were obtained with an Epson ES-1200S flat bed
scanner and Adobe Photoshop version 5.
Growth of Xenografts in nu/nu Mice
All animal experiments were carried out in accordance
with the animal protocol approved by the Institutional
Animal Care and Use Committee of the Shanghai
Tumor Institute. Although SKBr3 cells have been exten-
sively characterized in vitro, but this cell line failed to
be tumorigenic in nude mice. The impact of ARHI re-
expression on tumor growth in vivo was evaluated using
xenografts of the human breast cancer cell line MDA-
MB-231 in immunosuppressed Nu/Nu Balb/c nu/nu
mice. The MDA-MB-231 cells (3 × 106) were injected
subcutaneously into the mammary fat pad of each
mouse. The tumors were measured twice a week and
the tumor volumes were calculated using the formula
TV = (L × W2)/2, where L represents the longer dia-
meter and W represents the shorter diameter. When
palpable tumors had grown to a diameter of 0.3-0.5 cm,
the mice were divided into groups of six to eight, with
each group receiving a different treatment. For ARHI
treatment, the mice were intratumorally injected three
times per week for four to six weeks with 5 μg of ARHI
expression plasmid or pcDNA3 vector encapsulated
within liposomes (Sigma) at a ratio of 1:10 (DNA:lipo-
somes). As a control, the mice were injected with PBS
or liposomes only. The mice in the paclitaxel and pacli-
taxel/ARHI groups received 10 mg/kg of paclitaxel
intravenously three times per week during the same
interval.
Two days after the last treatment, two mice from each
group were sacrificed and the tumors were collected for
TEM analysis. The remaining animals were observed
until tumors in the control group reached a diameter of
~1.5 cm.
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Statistical analysis
The means ± SD were used for descriptive analyses.
ANOVA was used to assess the differences in means
among these groups, multiple comparisons between
each two groups were done by the LSD test, and the
mixed models were performed to assess the differences
in means among these groups for the repeated measure-
ment data. The criterion for statistical significance was
taken as p < 0.05 using a two-tailed t-test. The analyses
were performed using Stata 8.0 software.
Results
Re-expression of ARHI can be achieved in vitro and in vivo
The breast cancer cell lines SKBr3 and MDA-MB-231,
which express little endogenous ARHI, were used to
examine the effect of ARHI re-expression in cell cul-
ture. ARHI was strongly re-expressed in SKBr3 (Figure
1A) and MDA-MB-231 cells (data not shown) after
transfection with an ARHI construct. In MDA-MB-
231 cells, in which ARHI was hypermethylated, neither
DAC nor TSA alone affected the expression of ARHI;
however, robust re-expression of ARHI was detected
when cells were treated with a combination of DAC
and TSA, demonstrating that these two reagents have
synergistic effects (P < 0.001) (Figure 1B). In SKBr3
cells, in which ARHI was partially methylated, DAC
did not affect ARHI expression, while TSA alone
induced increased expression of ARHI (P < 0.001)
(Figure 1C).
We delivered an ARHI expression vector, using lipo-
somes in xenograft models and found that liposomal
delivery of ARHI is safe and efficient, permitting multi-
ple injections. Figure 1D shows that ARHI re-expression
can be detected at a higher level in the ARHI-liposomes
Figure 1 ARHI re-expression in breast cancer cells. (A) SKBr3 cells were transfected with pcDNA3-ARHI or pcDNA3 vector constructs.
Lipofectamine alone was used as a negative control. The ARHI expression was detected by western blot. (B) MDA-MB-231 cells and (C) SKBr3
cells were treated with DAC, TSA or a combination of DAC and TSA. The untreated cells and cells treated with DMSO diluent were used as
negative controls. The ARHI mRNA was detected by real-time quantitative RT-PCR and is presented as the fold change compared to the
negative control. *P < 0.05 or ***P < 0.001 compared to the DMSO diluent controls. The data were obtained from three independent
experiments. (D) ARHI expression in MDA-MB-231 xenografts was detected by real-time quantitative RT-PCR. It is presented as the fold change
compared to the PBS control. Each group included xenografts from two mice, and the data were replicated in three independent experiments.
**P < 0.01 compared to pcDNA3 vector/liposomes control.
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Figure 2 ARHI induces autophagy in breast cancer cells. (A) The detection of LC3 punctae. SKBr3 cells were co-transfected with GFP-LC3 and
ARHI or pcDNA3 vector. The cells transfected with GFP-LC3 alone and treated with rapamycin served as a positive control. The cells were
observed by fluorescence microscopy. The white arrows indicate LC3 punctae. (B) The autophagosomes were detected by TEM in xenografts
after treatment with ARHI-liposomes (N, nucleus; L, lysosome). The white arrows indicate autophagosomes. (C) ARHI re-expression increased
autophagy induction. SKBr3 cells were transfected with ARHI expression vector (left), MDA-MB-231 cells were transfected with ARHI expression
vector (middle) or SKBr3 cells were treated with TSA (right), and flow cytometry-AVO analysis was performed to examine autophagy induction.
The data were obtained from three independent experiments. (D) LC3 conversion and signaling. (Left) SKBr3 cells were stably transfected with
GFP-LC3 and subsequently transfected with ARHI or pcDNA3 vector constructs. LC3-I and LC3-II were detected by western blot. (Right) SKBr3
cells were transfected with ARHI expression vector. The pcDNA3 vector was used as the negative control. The pAKT, AKT, pmTOR, mTOR and
ARHI proteins were detected by western blot.
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group but not in the PBS control, liposomes, or
pcDNA3 vector-liposomes groups.
ARHI re-expression induces autophagy in breast cancer cells
SKBr3 breast cancer cells were co-transfected with GFP-
LC3 and ARHI to detect the effect of ARHI on the for-
mation of autophagic vesicles. Rapamycin-treated SKBr3
cells provided a positive control, whereas the cells trans-
fected with GFP-LC3 alone or GFP-LC3 and pcDNA3
vector served as negative controls. As presented in
Figure 2A, the cells transfected with ARHI had an
increased number of LC3 punctate spots, which mark
autophagosomes and represent the accumulation of a
membrane-bound form of LC3 on autophagic vesicles.
To further confirm that ARHI re-expression induced
autophagy, we performed ultrastructural studies using
TEM to detect the induction of autophagosomes in
xenografts. As shown in Figure 2B, the tissues that were
Figure 3 ARHI siRNA blocks TSA-mediated autophagy induction. (A) ARHI expression was knocking-down by siRNA. SKBr3 cells were treated
with TSA and siRNA-ARHI (siARHI). siRNA-control (siControl) was used as the negative control. ARHI expression was detected by real-time
quantitative RT-PCR. (B) TSA-mediated autophagy was blocked by ARHI siRNA. SKBr3 cells were treated with siControl or siARHI only, TSA
+siControl or TSA+siARHI. Autophagy was detected by Flow cytometry-AVO analysis. The experiments were repeated three times, *p < 0.05,
comparing with TSA/siControl. (C) One representive case of Flow cytometry-AVO analysis from (B). (D) Confocal fluorescent imaging of SKBr3
cells. The cells were co-transfected with a GFP-LC3 construct, and treated with siControl or siARHI only, TSA+siControl or TSA+siARHI.
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treated with ARHI-liposomes contained typical scattered
double-membrane vacuolar structures. Autophagosomes
were not found in xenografts treated with PBS, lipo-
somes or pcDNA3 vector-liposomes.
When ARHI was activated by transfection (Figure 2C
left, middle) or by drugs (TSA, Figure 2C right), flow
cytometry-AVO analysis showed the autophagy rate was
greatly increased. Expression of ARHI increased the
conversion of GFP-LC3-I to GFP-LC3-II (Figure 2D
left), and ARHI re-expression decreased the phosphory-
lation of AKT and mTOR, which are known inhibitors
of autophagy (Figure 2D right).
ARHI is required for the induction of autophagy
In all probability, treatment with TSA and DAC upregu-
lates many genes in addition to ARHI. To determine the
role of ARHI in the induction of autophagy, we used
siRNA to knock down ARHI specifically in SKBr3 cells.
TSA treatment upregulated the expression of ARHI, but
this upregulation did not occur in the cells transfected
with siRNA-ARHI (Figure 3A). Using flow cytometry-
AVO analysis (Figure 3B, C) and imaging of LC3 punc-
tate spots (Figure 3D), we observed that TSA treatment
enhanced autophagy, but transfection with siRNA-ARHI
blocked the effects of TSA, demonstrating that ARHI is
essential for autophagy induction.
Re-expression of ARHI enhances the inhibitory effects of
paclitaxel on breast cancer cell growth
Our recent studies showed that ARHI re-expression can
induce autophagic cell death. Under certain conditions,
however, ARHI can induce tumor dormancy. To overcome
tumor dormancy, we have studied the effects of combined
autophagy and apoptosis. Paclitaxel, a cytotoxic drug, can
inhibit cancer cell growth by inducing apoptosis and G2/M
cell cycle arrest. TSA, an HDAC inhibitor, can activate sev-
eral tumor suppressor genes, including ARHI, and induce
autophagy. In combination assays, TSA greatly enhanced
the inhibitory effect of paclitaxel on the growth of SKBr3
cells (P < 0.01 or P < 0.001; Figure 4A). To test if ARHI
gene delivery has the same effect, an ARHI expression vec-
tor was delivered by intratumoral injection of liposomes.
Growth of MDA-MB-231 xenografts was significantly
inhibited by ARHI-liposomes, liposomes or pcDNA3 vec-
tor-liposomes only showed weaker inhibition (Figure 4B).
The tumors treated with a combination of ARHI and pacli-
taxel grew significantly more slowly (p < 0.05) than the
controls, whereas the individual treatments did not signifi-
cantly inhibit tumor growth (Figure 4C). Thus, ARHI-lipo-
somes enhanced the antitumor activity of paclitaxel.
Paclitaxel increases ARHI-induced autophagy
While paclitaxel alone did not induce autophagy in either
MDA-MB-231 or SKBr3 cells, flow cytometry-AVO
analysis showed that paclitaxel treatment enhanced
ARHI-induced autophagy (Figure 5A, B). ARHI re-
expression was performed by transfection (Figure 5A, B)
or by TSA treatment (data not shown).
ARHI re-expression promotes paclitaxel-induced
apoptosis
Apoptosis was measured using an annexin V/PI double
staining method and flow cytometry analysis. As epige-
netic regulators, DAC and TSA can activate several
tumor suppressor genes, including ARHI. When DAC
and TSA were combined with paclitaxel in MDA-MB-
231 cells, or TSA was combined with paclitaxel in
Figure 4 ARHI re-expression enhances the inhibitory effects of
paclitaxel in vitro and in vivo. (A) SKBr3 cells were treated with
paclitaxel (P), TSA (4-15 nM), or a combination of both drugs. The
inhibitory rate was detected by SRB assays after three days of
culture. **P < 0.01, ***P < 0.001 compared to paclitaxel alone. (B)
MDA-MB-231 xenografts were treated with liposomes, pcDNA3
vector/liposomes or ARHI/liposomes. PBS was used as a control.
*P < 0.05 compared to control group. (C) MDA-MB-231 xenografts
were treated with paclitaxel, ARHI-liposomes or a combination of
paclitaxel and ARHI-liposomes. PBS was used as a control. *P < 0.05
compared to control group.
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SKBr3 cells, respectively (Figure 5C), the number of
apoptotic cells significantly increased. In the xenograft
model, while autophagosomes were seen in TEM images
of the tissues from the mice treated with ARHI-
liposomes (Figure 2D), few apoptotic cells were seen in
this group. Only classic apoptotic cells with characteris-
tic chromatin condensation and no autophagosomes
were seen in tissues from mice treated with paclitaxel.
Few autophagic or apoptotic cells were found in the tis-
sues from control mice. Significantly more apoptotic
and autophagic cells were found in the tissues from the
mice treated with a combination of ARHI and paclitaxel
(Figure 5D).
ARHI re-expression increases paclitaxel-induced G2/M cell
cycle arrest
Paclitaxel is known to induce cell cycle arrest at the G2/
M phase. When MDA-MB-231 cells were treated with
DAC/TSA in combination with paclitaxel, the frequency
of cells arrested at the G2/M phase was dramatically
increased (Table 1, Figure 6) compared to the cells trea-
ted with paclitaxel alone. Similar results were found in
the SKBr3 cells (Table 2).
Figure 5 Autophagy and apoptosis are enhanced by the combination of ARHI re-expression and paclitaxel. ARHI-induced autophagy is
increased by the addition of paclitaxel in SKBr3 (A) and MDA-MB-231 (B) cells. The cells were transfected with pcDNA3-ARHI or pcDNA3 vector
constructs. Cells treated with lipofectamine only or DMSO diluent served as negative controls. After 24 hours, paclitaxel was added. Flow
cytometry-AVO analysis was performed after 48 hours. *P < 0.05 compared to control. The data were obtained from three independent
experiments. (C) Paclitaxel-induced apoptosis is increased by ARHI re-expression. MDA-MB-231 cells or SKBr3 cells were treated with paclitaxel,
DAC, TSA, or a combination. The rate of apoptosis was analyzed by annexin-flow cytometry after 48 hours. **P < 0.01 compared to control. The
data were obtained from three independent experiments. (D) Both apoptotic cells (left) and autophagic cells (right) were detected by TEM in
xenograft tumors that received paclitaxel/ARHI combination treatment.
Table 1 The Cell Cycle Analysis of MDA-MB-231 Cells
MDA-MB-231 G0/G1 (%) S (%) G2/M (%)
Control 52.70 ± 0.52 43.35 ± 0.95 4.05 ± 0.43
DMSO 55.23 ± 1.17 39.69 ± 2.04 5.09 ± 2.31
TSA 59.25 ± 0.64 35.45 ± 0.38 5.30 ± 0.34*
DAC 46.91 ± 0.16 43.11 ± 0.19 9.98 ± 0.29***
DAC+TSA 46.42 ± 0.81 27.30 ± 1.59 25.29 ± 2.65**
Paclitaxel 42.85 ± 6.51 45.13 ± 5.21 12.01 ± 3.43*
DAC+TSA+Paclitaxel 39.67 ± 2.12 14.6 8 ± 1.87 45.99 ± 0.32***
*P < 0.05, **P < 0.01, ***P < 0.001 compared to control. The data were obtained
from three independent experiments and are presented as the mean ± SD.
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Figure 6 G2/M cell cycle arrest rate is increased in cells treated with a combination of TSA/DAC and paclitaxel. (A) MDA-MB-231 cells
were treated with paclitaxel, DAC, TSA, or a combination. The cell cycle status was detected by PI staining and flow cytometry analysis 48 hours
after treatment. The data were obtained from three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001 compared to control. (B) Flow
cytometry data from one representative experiment.
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Discussion
Autophagy is a major intracellular pathway for protein
degradation, recycling proteins and eliminating aged or
damaged organelles. The process begins with the
sequestration of cellular organelles and cytoplasm in a
double-membrane autophagosome. Autophagosomes
then fuse with lysosomes, and the materials inside are
degraded to amino acids and fatty acids. Autophagy is
rapidly induced when the cells need to eliminate
damaged cytoplasmic components or organelles as well
as during oxidative stress, infection, ischemia-reperfu-
sion or mitochondrial dysfunction. Some drugs, such as
rapamycin, induce autophagy. Recently, we reported that
the tumor suppressor ARHI regulates autophagy and
tumor dormancy in ovarian cancer cells. Re-expression
of ARHI in multiple human ovarian cancer cell lines
induces autophagy by blocking PI3K signaling, inhibiting
mammalian target of rapamycin (mTOR), and upregu-
lating ATG4. ARHI also colocalizes with MAP-LC3 in
autophagosomes. Furthermore, ARHI is required for
spontaneous and rapamycin-induced autophagy in nor-
mal and malignant cells [12]. The present study further
confirms that the re-expression of ARHI induces autop-
hagy in breast cancer cells and enhances the inhibitory
effects of paclitaxel. ARHI activation could be used as a
new therapeutic strategy in breast cancer.
Although apoptotic cell death in cancer has been
intensively studied over the last decade, the role of
autophagy in cell death has received less attention.
Autophagy has recently emerged as an important media-
tor of the programmed cell death (PCD) pathway. Under
certain circumstances, the inhibition of autophagy can
trigger apoptosis, and the upregulation of autophagy
protects against the onset of apoptosis [15]. By contrast,
autophagy can function as a second mode of PCD (Type II
PCD) that is distinct from apoptosis [16]. Some reports
suggest that autophagy protects cells from nutrient
depletion stress, but paradoxically, excessive autophagy
results in cell death. These results also suggest that the
induction of autophagy depends on orchestrated interac-
tions between cancer cells and other cells in the tumor
microenvironment during the neoplastic process [17].
Moreover, tumorigenesis is associated with the downre-
gulation of autophagy, and genes that mediate autophagy
have been shown to be tumor suppressors [18]. In this
study, we addressed the question of what happens when
autophagy meets apoptosis by combining agents that
induce autophagy and apoptosis and observing their
interaction [19]. Our studies revealed that TSA and DAC
could activate ARHI expression and induces autophagy,
but not apoptosis; it is true that this treatment modulated
more genes, but we further confirmed that ARHI is
required during autophagy induction. When TSA and
DAC were combined with paclitaxel, a chemotherapy
agent that induces apoptosis, we observed additive inhibi-
tory effects on breast cancer cell growth. Paclitaxel alone
did not induce autophagy in these breast cancer cell
lines, but an increased fraction of autophagic cells was
found when paclitaxel was combined with TSA and
DAC. Conversely, apoptosis was not induced when ARHI
was activated by TSA and DAC, but the fraction of apop-
totic cells was increased when paclitaxel was added.
Whether the induction of autophagy contributes to
cell survival or death during apoptosis may relate to
the level and duration of autophagy. Low levels of
autophagy could promote survival by eliminating
damaged intracellular proteins and organelles. This
process could increase cell survival by preventing
apoptosis. Conversely, excessive autophagy, such as
that observed during the induction of ARHI re-expression
by TSA and DAC, eventually led to the destruction of
essential proteins and organelles beyond a certain thresh-
old, resulting in cell death. In examining various signaling
pathways, we found ARHI re-expression mainly inhibited
the autophagy-related pathways, such as pAKT and
pmTOR (Figure 2), while paclitaxel mainly inhibited the
apoptosis-related pathway. When these signaling changes
were combined, cancer cell death was hastened. Our stu-
dies may thus shed light on a new approach for combining
ARHI gene therapy with chemotherapy.
Conclusions
A tumor suppressor gene, ARHI, induces autophagy in
breast cancer cells, and ARHI is essential for the
induction of autophagy. When ARHI was re-expressed
in breast cancer cells treated with paclitaxel, the
growth inhibitory effect of paclitaxel was enhanced by
promoting autophagy, apoptosis, and G2/M cell cycle
arrest.
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